Concarlo Is On A Mission To Rid The World Of Metastatic Breast Cancer

Join this webinar to hear from Concarlo’s CEO and CSO Dr. Stacy Blain and COO LisaMarie Casey as they discuss the science behind a remarkable breakthrough in the treatment of metastatic cancers.

The Cancer Moonshot: A 5 Year Review

Watch our webinar to learn about the incredible progress that’s being made to achieve these goals and what is still on the horizon.

RESI Certificate 1st Prize (Concarlo Holdings)

RESI Innovator’s Pitch Challenge Winner

Concarlo wins the Innovator’s Pitch Challenge at RESI Jan 2021!

Targeting p27Kip1 to Treat Drug-Resistance Cancer

Stacy Blain, PhD, Founder, CSO and CEO

US biotech start-up set to have huge impact on breast cancer treatment landscape

Click to read the Drug Discovery World article about Concarlo, also featured in their fall issue.

Concarlo: targeting proliferation and resistance in one go

Click to read the BioCentury Emerging Company Profile.

TigerTalks in the City: How Genomics Are Driving Novel Therapies

Stacy was a panelist at Princeton Entrepreneurship Council’s popular panel discussion series. Click to learn more.

2019 Social Enterprise Conference

Stacy Blain was a panelist at Columbia University’s Social Enterprise Conference.

WE NYC Women in Tech Conference

Stacy Blain was a panelist at WE NYC’s annual summit, Female Founders Disrupting HealthTech, at the New York Genome Center.

NYU Female Founders Forum

Stacy presenting on April 12, 2019.

Impact Journals: March 2019

Click here to download the manuscript: Tyrosine Phosphorylation of p27Kip1 Correlates with Palbociclib Responsiveness in Breast Cancer Tumor Cells Grown in Explant Culture

Proactive Investors Interview

At the 11th Annual Biotech Showcase in San Francisco

Women & Wealth Magazine: 18 Women to Watch in 2018

Features Dr. Stacy Blain, Co-Founder and Chief Scientific Officer, Concarlo Holdings

SUNY Downstate Medical Center Press Release

SUNY Downstate Startup Company Secures Over $1 Million in Seed Funding Investment for Advancement of Proprietary Cancer Companion Diagnostic Test

Newsday Business Article

LI venture capital fund invests in NYC biotech startup

Impact Journals: Oncoscience May 2018

Click here to download Stacy’s article: Targeting p27 tyrosine phosphorylation as a modality to inhibit CDK4 and CDK2 and cause cell cycle arrest in breast cancer cells.

Molecular Cancer Research Journal: March 2018

Click here to download Stacy and Priyank’s article:
Dual Inhibition of CDK4 and CDK2 via Targeting p27 Tyrosine Phosphorylation Induces a Potent and Durable Response in Breast Cancer Cells

Going Through It Together

Stacy and Catherine’s Grand Canyon Hike

Student Visit from Edsnaps

Increasing diversity in the science technology engineering & mathematics (STEM) workforce.

Research Associate Sarah Teed, M.S. welcomes young students to learn more about Concarlo’s mission.